Treace Medical Concepts, Inc.
TMCI
$6.72
$0.060.90%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 209.36M | 202.86M | 198.53M | 196.03M | 187.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 209.36M | 202.86M | 198.53M | 196.03M | 187.12M |
| Cost of Revenue | 41.09M | 39.33M | 38.38M | 37.27M | 35.18M |
| Gross Profit | 168.26M | 163.53M | 160.16M | 158.76M | 151.94M |
| SG&A Expenses | 203.36M | 206.27M | 206.19M | 198.10M | 187.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 264.94M | 265.07M | 263.43M | 252.60M | 238.55M |
| Operating Income | -55.58M | -62.21M | -64.90M | -56.57M | -51.43M |
| Income Before Tax | -55.74M | -61.52M | -63.68M | -54.75M | -49.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -55.74 | -61.52 | -63.68 | -54.75 | -49.53 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.74M | -61.52M | -63.68M | -54.75M | -49.53M |
| EBIT | -55.58M | -62.21M | -64.90M | -56.57M | -51.43M |
| EBITDA | -48.16M | -54.76M | -58.04M | -50.73M | -46.58M |
| EPS Basic | -0.90 | -0.99 | -1.03 | -0.89 | -0.82 |
| Normalized Basic EPS | -0.56 | -0.62 | -0.64 | -0.55 | -0.51 |
| EPS Diluted | -0.90 | -0.99 | -1.03 | -0.89 | -0.82 |
| Normalized Diluted EPS | -0.56 | -0.62 | -0.64 | -0.55 | -0.51 |
| Average Basic Shares Outstanding | 248.44M | 247.80M | 247.14M | 246.44M | 243.37M |
| Average Diluted Shares Outstanding | 248.44M | 247.80M | 247.14M | 246.44M | 243.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |